High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

摘要: 2 Background: The humanized monoclonal antibody bevacizumab (BEV) binds VEGF, inhibits angiogenesis, and improves survival when combined with chemotherapy for advanced colorectal cancer. Methods: E3200 is a randomized phase 3 trial of high-dose BEV (10 mg/kg, IV, biweekly) either alone, or in combination FOLFOX4 (biweekly administration of: oxaliplatin 85 mg/m2, day 1; leucovorin 200 mg/m2 IV 2hrs fluorouracil 400 bolus followed by 600 CIV 22hrs, days 1 & 2), compared to patients previously treated Eligible had an ECOG PS 0–2 must have been fluoropyrimidine irinotecan-based regimen used alone combination. Prior use was not allowed. endpoints include (OS), progression free (PFS) response rate (RR). Results: 829 were accrued from November 2001 April 2003. arm the study closed March 200...